Skip to content
TriangleGet started
← Childhood Rhabdomyosarcoma

FOR PATIENTS · SOURCE READING

Targeted therapy

Source: Childhood Rhabdomyosarcoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: April 8, 2022 · Captured 2026-09-09.

Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary. Independent clinical review is pending.

Context: Treatment Option Overview / New types of treatment are being tested in clinical trials.

Targeted therapy is a type of treatment that uses drugs or other substances to identify and attack specific cancer cells. Targeted therapies usually cause less harm to normal cells than chemotherapy or radiation therapy do. There are different types of targeted therapy:

Source links and citations

mTOR inhibitors stop the protein that helps cells divide and survive. Sirolimus is a type of mTOR inhibitor therapy being studied in the treatment of recurrent rhabdomyosarcoma.

Source links and citations

Tyrosine kinase inhibitors block signals that cancer cells need to grow and divide. MK-1775, cabozantinib-s-malate, and palbociclib are tyrosine kinase inhibitors being studied in the treatment of newly diagnosed or recurrent rhabdomyosarcoma.

Source links and citations

Preserved source evidence · Independent clinical review pending · Not medical advice